Company Filing History:
Years Active: 1992
Title: Klaus Schollmeier: Innovator in Polypeptide Pharmaceuticals
Introduction
Klaus Schollmeier is a notable inventor based in Hemsbach, Germany. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on polypeptides. His research focuses on the manipulation of lymphotoxin, which has important implications for medical applications.
Latest Patents
Klaus Schollmeier holds a patent for "N-terminal deletions of lymphotoxin, their preparation and use." This patent describes polypeptides that differ from lymphotoxin by the absence of amino acids at the N-terminal end. These polypeptides can be prepared through gene manipulation and are suitable for use as pharmaceuticals, either alone or in combination with lymphokines.
Career Highlights
Schollmeier is associated with BASF Aktiengesellschaft, a leading chemical company known for its innovative research and development. His work at BASF has allowed him to explore the potential of polypeptides in therapeutic applications, contributing to advancements in the pharmaceutical industry.
Collaborations
Throughout his career, Klaus Schollmeier has collaborated with esteemed colleagues such as Achim Moeller and Wolfgang Koerwer. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.
Conclusion
Klaus Schollmeier's contributions to the field of polypeptide pharmaceuticals highlight his innovative spirit and dedication to advancing medical science. His work continues to influence the development of new therapeutic options, showcasing the importance of research and collaboration in the pharmaceutical industry.